The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
The Deputy Minister of Health of the Russian Federation, Evgeny Kamkin, announced that the overall mortality rate of Russians in 2023 has decreased by an impressive 7%. As specified, this is the best indicator since the COVID-19 pandemic.
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Hungary, Serbia, and Russia have agreed to collaborate on joint projects in the field of nuclear medical technologies, focusing on cancer treatment. This agreement was reached during the international forum Atomexpo-2024, held in Sochi.
Researchers propose novel test for pyrogen detection
27 March 2024
An alternative in vitro pyrogen detection test using transfected THP-1 cells detected endotoxin and nonendotoxin pyrogens with good sensitivity, stability and predictability, a study shows.
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024
A Phase III trial has shown that compared to oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients.
Innate drops monotherapy plans for lacutamab in one type of lymphoma after hold lift
26 March 2024
Just two months after the FDA lifted a clinical hold on trials of Innate Pharma’s lymphoma drug, the biotech has now dropped plans to pursue the anti-KIR3DL2 antibody as a monotherapy for a specific form of that cancer.
Control strategy could facilitate faster bioburden detection
26 March 2024
Biopharma and bioprocessing experts have proposed an approach that uses a two-tiered control strategy for rapid bioburden testing, that can beneficially, “leverage faster detection times”. It comprises of a “fast (but possibly less sensitive) test” for process monitoring which then initiates “action for a second, longer duration test which is used to confirm and quantify the presence of bioburden and identify the [ microbial ] organism.”
Combination treatment could minimise cancer relapse risk
25 March 2024
Data suggests that ribociclib plus endocrine therapy could provide a new treatment option more patients with HR-positive, HER2-negative early breast cancer.
25 March 2024
Construction of the largest genetics center in Russia has entered its second stage, with development underway on the premises of Sirius University. It is planned to create and equip more than 100 premises for laboratory research, including a center for preclinical research using laboratory animals and infrastructure for implementing projects in the field of paleogenetics.
In Russia, lutetium-177 is used to treat neuroendocrine tumors for the first time
22 March 2024
The Federal State Budgetary Institution Scientific Research Center for Radiology of the Ministry of Health of Russia has successfully utilized a Russian radiopharmaceutical drug based on lutetium-177 to treat patients with metastatic and inoperable neuroendocrine tumors for the first time. Both patients were diagnosed with a neuroendocrine tumor of the pancreas, progressing against the background of standard chemotherapy.
In 2023, Russia has registered 540 drugs
22 March 2024
In 2023, the Russian Ministry of Health registered a total of 540 medicines, with less than half, specifically 160 (29.6%), being of foreign origin. This was stated by the head of the department, Mikhail Murashko, emphasizing that “Russian pharma has begun to create innovative products.”
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024